# FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Source: https://onco.cc/trials/nct06636682/  
OnCo record `nct06636682` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FK-PC101 in prostate cancer, run by Cellvax Therapeutics Inc, now recruiting.

## Summary

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer is a phase 2 interventional study registered as NCT06636682 by Cellvax Therapeutics Inc, with 100 participants planned, started 2024-10-14 and due to reach its primary completion in 2027-02-02. Interventions recorded: FK-PC101 and Standard of Care (SOC).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06636682
- Phase: 2
- Setting: A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy
- Sponsor: Cellvax Therapeutics Inc
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06636682: https://clinicaltrials.gov/study/NCT06636682

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06636682.json